Fig. 1 · Structure

Documents & Downloads

Diclofenac sodium

Cat. No. A10304 CAS 15307-79-6

COX inhibitor

Diclofenac Sodium is a non-selective COX inhibitor with IC50 of 0.5 μg/ml and 0.5 μg/ml for COX-1 and -2 in intact cells, respectively, used as a nonsteroidal anti-inflammatory drug (NSAID) to relieve pain and reduce swelling in flammation.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Diclofenac sodium inhibited functional COX-1 and COX-2 activity in human whole blood, measured through TXB2 and PGE2 production. Preferential COX-2 inhibition in this assay coexisted with COX-1 inhibition at higher concentrations. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
COX-1 60 nM
COX-2 200 nM

In Vitro Studies

In a human whole-blood assay, diclofenac sodium had reported IC50 values of 36.2 ng/mL for COX-1 and 13.5 ng/mL for COX-2. Corresponding IC80 values were 294.4 and 51.3 ng/mL. These assay concentrations do not establish clinical efficacy or formulation safety. [1]

COX inhibition in human whole blood

Cell-based study · Human whole blood from healthy Japanese volunteers aged 20–40 years; 8 male and 10 female participants enrolled [1]

Both prostanoid readouts were inhibited with increasing concentration; the COX-2 IC50 was lower. This cellular blood assay measures functional COX activity rather than direct binding.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
TXB2 production, COX-1 assayIC50 36.2 ng/mL[1]
PGE2 production, COX-2 assayIC50 13.5 ng/mL[1]
TXB2 production, COX-1 assayIC80 294.4 ng/mL[1]
PGE2 production, COX-2 assayIC80 51.3 ng/mL[1]

Literature-Reported Treatment Conditions

Treatment concentration
4.12–1000 ng/mL final diclofenac sodium
Exposure duration
COX-1: 1 h; COX-2: 24 h
Method
Whole-blood prostanoid assays; COX-2 readout after aspirin pretreatment and inflammatory stimulation
Vehicle
DMSO
Co-treatment
Aspirin pretreatment is an assay control for the COX-2 readout, not an efficacy combination.
Reported limits
Figure 1 reports mean ± SE for five samples; donor-to-sample independence is not fully clarified. No uncertainty intervals accompany Figure 2 IC values.
Methods and source locations

Compound reported in the paper: Diclofenac sodium; Compound label in the paper: FUJIFILM Wako Pure Chemical material

Sodium-salt functional COX inhibition in human blood; no conversion of units or clinical dosing inference.

Methods: Preparation of Samples, COX-1 and COX-2 Assays, Calculation of Inhibition Rates, Statistical Analysis; Figure 1a and caption; Figure 2 labeled IC50/IC80 lines; Discussion limitations

TXB2 production, COX-1 assay: ELISA and logistic fit — Figure 2, labeled COX-1 IC50 line

PGE2 production, COX-2 assay: ELISA and logistic fit — Figure 2, labeled COX-2 IC50 line

TXB2 production, COX-1 assay: ELISA and logistic fit — Figure 2, labeled COX-1 IC80 line

PGE2 production, COX-2 assay: ELISA and logistic fit — Figure 2, labeled COX-2 IC80 line

In Vivo Studies

As a separate comparator treatment in female BALB/c mice, diclofenac sodium (10 mg/kg, intraperitoneal) given 1 h before carrageenan reduced baseline-corrected paw edema by a reported 56.05% at 5 h versus saline control (n=6/group). This acute experiment does not establish chronic efficacy or safety. [2]

Diclofenac sodium comparator in acute mouse paw edema

Animal study · Female BALB/c mice aged 6–8 weeks with carrageenan-induced paw edema [2]

A single diclofenac sodium pretreatment reduced acute paw edema relative to saline control. This is an acute comparator experiment in a gelsolin study.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Baseline-corrected paw edema at 5 h versus saline controlPercent inhibition 56.05%[2]

Conditions shared by the study groups

Route
Intraperitoneal
Frequency
Single pretreatment
Treatment course
1 h before carrageenan; paw edema monitored through 5 h
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Diclofenac sodium comparator
10 mg/kg
Saline control, 0.2 mL/mouse intraperitoneally (Table 4); methods describe placebo 10 mL/kgTable 4 reports 56.05% inhibition of baseline-corrected paw edema at 5 h versus control.[2]
Diclofenac sodium comparator
Model: Female BALB/c mice, 6–8 weeks; carrageenan-induced paw edema; n=6/group
Reported limits: Diclofenac solution composition and randomization/blinding are not specified in the selected reported methods. Control volume is expressed differently in methods and table; these are retained without assumed equivalence.
Methods and source locations

Compound reported in the paper: Diclofenac sodium; Compound label in the paper: Himedia material; standard drug comparator

Acute edema comparator result for sodium salt; no chronic efficacy or safety extrapolation.

Materials and Methods: Drugs, Chemicals and Reagents, Experimental Mice, Carrageenan-induced paw edema in mice, Statistical analysis; Results corresponding subsection; Figure 4 and Table 4 (PDF page 9)

Baseline-corrected paw edema at 5 h versus saline control: Vernier-caliper measurements; baseline-corrected inhibition formula in Methods. n=6/group; general statistics state mean ± SD; percentage has no reported uncertainty. — Table 4; Figure 4 caption; Methods: Carrageenan-induced paw edema in mice and Statistical analysis

Diclofenac sodium comparator · Materials and Methods: Drugs, Chemicals and Reagents, Experimental Mice, Carrageenan-induced paw edema in mice, Statistical analysis; Results corresponding subsection; Figure 4 and Table 4 (PDF page 9)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 15307-79-6
Applications COX inhibitor
Formula C14H10Cl2NNaO2
Molecular Weight 318.13
SMILES
C1=CC=C(C(=C1)CC(=O)[O-])NC2=C(C=CC=C2Cl)Cl.[Na+]

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 54 mg/mL (169.74 mM)
Water 12 mg/mL (37.71 mM)
Ethanol 54 mg/mL (169.74 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Kenshu Shirakawa, Masafumi Takeno, Hidekazu Kuma, et al. Comparative Evaluation of Cyclooxygenase Inhibition Profiles Across Various NSAID Forms and Doses: Implications for Efficacy and Adverse Effects Pain and Therapy (2025). PMID: 39688800 DOI: 10.1007/s40122-024-00687-2 Source material
  2. [2] Ashok Kumar Gupta, Devraj Parasar, Amin Sagar, et al. Analgesic and Anti-Inflammatory Properties of Gelsolin in Acetic Acid Induced Writhing, Tail Immersion and Carrageenan Induced Paw Edema in Mice PLOS ONE (2015). PMID: 26426535 DOI: 10.1371/journal.pone.0135558 Source material

Added to your cart

View Cart Checkout
Loading...